Fahim Thanaa M, Mohamed Marwa Abd El-Hameed, Abdelrahman Sahar S M, Lotfy Dina M
Drug Radiation Research Department, National Center for Radiation Research and Technology (NCRRT), Egyptian Atomic Energy Authority (EAEA), Cairo, Egypt.
Department of Pathology, College of Veterinary Medicine, Cairo University, Cairo, Egypt.
Dose Response. 2023 May 27;21(2):15593258231179900. doi: 10.1177/15593258231179900. eCollection 2023 Apr-Jun.
The present study investigates the new approach of rosuvastatin (RUV) administration as a drug for the management of spleen injury induced by gamma irradiation.
Forty rats were used and divided equally into 4 groups: control group, irradiated group, IRR + rosuvastatin group (10 mg/Kg b. wt), and IRR + rosuvastatin group (20 mg/kg b. wt) for 7 days orally.
The possible curative effect can be illustrated via the improvement of hematopoietic cell count (Hb, RBCs, and WBCs) and oxidative stress markers (MDA and GST) in addition to biochemical parameters including [heme oxigenase-1 (HO-1), nuclear erythroid 2-related factor (Nrf2), NOD-, LRR- and pyrin domain- containing protein 3 (NLRP3) inflammasome] and immune assay of nuclear factor kappa beta (NF-kB P65) and inducible nitric oxide synthase (iNOS). Histological pictures emphasize the biochemical findings. Rosuvastatin treatments by using two different doses improve the tested parameters. High-dose administration of RUV (20 mg/kg p.o.) recorded better results than the low dose (10 mg/kg p.o.).
Our results suggested that rosuvastatin reversed the radiation-induced spleen-damaging effects. So, RUV can be introduced to the market as a new therapy for the management of spleen damages.
本研究探讨瑞舒伐他汀（RUV）作为一种药物用于管理γ射线诱导的脾脏损伤的新方法。
使用40只大鼠，将其平均分为4组：对照组、辐照组、IRR + 瑞舒伐他汀组（10毫克/千克体重）和IRR + 瑞舒伐他汀组（20毫克/千克体重），口服给药7天。
除了包括[血红素加氧酶-1（HO-1）、核红细胞2相关因子（Nrf2）、含NOD、LRR和吡啉结构域的蛋白3（NLRP3）炎性小体]的生化参数以及核因子κB（NF-kB P65）和诱导型一氧化氮合酶（iNOS）的免疫测定外，还可通过改善造血细胞计数（血红蛋白、红细胞和白细胞）和氧化应激标志物（丙二醛和谷胱甘肽S-转移酶）来说明可能的治疗效果。组织学图片强调了生化结果。使用两种不同剂量的瑞舒伐他汀治疗可改善测试参数。高剂量（20毫克/千克口服）的RUV给药记录的结果优于低剂量（10毫克/千克口服）。
我们的结果表明瑞舒伐他汀可逆转辐射诱导的脾脏损伤作用。因此，RUV可作为一种治疗脾脏损伤的新疗法推向市场。
